Table 2 Comparison of clinical characteristics between patients with and without a cough
Characteristic | Subgroup | Cough, N (%) | No Cough, N (%) | p-value |
|---|---|---|---|---|
Mean age in years (SD) | 67 years (9.02) | 66 years (8.85) | 0.56 | |
Male sex | 57 (50) | 49 (56) | 0.34 | |
Smoking status | Never smoked | 12 (10) | 7 (8) | 0.44 |
Former | 73 (64) | 62 (72) | ||
Current | 30 (26) | 17 (20) | ||
Median no. pack years on ever smokers (25th–75th IQR) | 38 (17.5–46) | 33 (17.5–50) | 1.00 | |
Performance status | 0 | 15 (13) | 12 (14) | 0.09 |
1 | 33 (29) | 39 (45) | ||
2 | 46 (40) | 25 (29) | ||
3 | 21 (18) | 11 (12) | ||
Stage | Early NSCLC (incl IIIA) | 14 (12) | 12 (14) | 0.61 |
Advanced NSCLC | 63 (56) | 47 (55) | ||
Limited stage SCLC | 12 (11) | 5 (6) | ||
Extensive stage SCLC | 24 (21) | 22 (25) | ||
Histology | Non-small cell lung cancer | 76 (67) | 59 (68) | 1.00 |
Small cell lung cancer | 36 (31) | 27 (31) | ||
Mixed | 2 (2) | 1 (1) | ||
Non-small cell lung cancer histological subtype | Adenocarcinoma | 44 (55) | 40 (65) | 0.29 |
Squamous | 25 (31) | 16 (26) | ||
Not otherwise specified | 10 (13) | 3 (5) | ||
Mixed | 1 (1) | 1 (2) | ||
Large cell | 0 (0) | 1 (2) | ||
On anticancer therapy | Yes | 45 (40) | 47 (54) | 0.04 |
What type of anticancer therapy | Chemotherapy | 28 (62) | 30 (65) | 0.44 |
Radiotherapy | 3 (7) | 0 (0) | ||
Concurrent | 2 (4) | 2 (4) | ||
Tyrosine-kinase inhibitors | 12 (27) | 14 (31) | ||
If not on anticancer therapy, why not | Pre-treatment | 16 (23) | 13 (31) | 0.33 |
Post palliative treatment | 24 (34) | 18 (43) | ||
Post curative treatment | 6 (9) | 3 (7) | ||
No further treatment | 24 (34) | 8 (19) | ||
Comorbidities | Nausea | 42 (36) | 33 (38) | 0.79 |
Gastro-oesophageal reflux | 62 (54) | 44 (51) | 0.70 |